

WEST Search History

DATE: Tuesday, November 12, 2002

<u>Set Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
side by side			
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES;</i>			
<i>OP=AND</i>			
L1	moraxella.ti.	133	L1
L2	moraxella.ti. and bovis!.ti.	11	L2

END OF SEARCH HISTORY

WEST

Generate Collection

Print

L2: Entry 1 of 11

File: USPT

Jun 23, 1987

US-PAT-NO: 4675176

DOCUMENT-IDENTIFIER: US 4675176 A

TITLE: Moraxella bovis protease vaccine

DATE-ISSUED: June 23, 1987

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gerber; Jay D.	Lincoln	NE		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Norden Laboratories	Lincoln	NE			02

APPL-NO: 06/ 560780 [PALM]

DATE FILED: December 12, 1983

INT-CL: [04] A61K 37/48, A61K 39/00, C12N 9/52

US-CL-ISSUED: 424/88; 424/92, 435/220

US-CL-CURRENT: 424/251.1; 424/823, 435/220

FIELD-OF-SEARCH: 424/92, 424/88, 424/94, 435/212, 435/219, 435/220

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected

Search ALL

	PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
<input type="checkbox"/>	<u>3197373</u>	July 1965	Jackson	424/92
<input type="checkbox"/>	<u>3401219</u>	September 1968	Zeissig	424/92
<input type="checkbox"/>	<u>3853990</u>	December 1974	Madigan et al.	424/87
<input type="checkbox"/>	<u>4254098</u>	March 1981	Graham, Jr. et al.	424/14

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
107845	October 1982	EP	

OTHER PUBLICATIONS

Frank, Sandra K. and Jay D. Gerber, "Hydrolytic Enzymes of Moraxella bovis," J. of Clin. Imm., Feb. 1981, pp. 269-271.

Hughes, D. E., et al., Am. Journal Vet. Res., vol. 38, No. 11 (Nov. 1977) pp. 1905-1907.

Sandhu, T. S. and Franklin H. White, "Extracellular Antigens of Moraxella bovis," Am. Journal of Vet. Res., vol. 37, pp. 1119-1122, Sep. 1976.

Windholz, et al., (Ed.) The Merck Index (10th ed.) 1983, p. 1126 (#7721).

Van Bijsterveld, O. P.; "Bacterial Proteases in Moraxella Angular Conjunctivitis," Amer. J. of Ophthalmology, vol. 72, No. 1, (1971); pp. 181-184.

Frank et al.; "Hydrolytic Enzymes of Moraxella bovis"; Chemical Abstracts, vol. 94, No. 15, Apr. 13, 1981; p. 349, Abstract No. 117523e.

Pugh et al., Can. J. Comp. Med. 37:70-78 (1973).

PILIGUARD.TM. product bulletin.

ART-UNIT: 127

PRIMARY-EXAMINER: Wiseman; Thomas G.

ASSISTANT-EXAMINER: Weimar; Elizabeth C.

ABSTRACT:

Protease produced by Moraxella bovis can be used as an immunoprophylactic agent for protection against infection by M. bovis.

31 Claims, 0 Drawing figures

WEST

Generate Collection

Print

L2: Entry 2 of 11

File: EPAB

May 9, 1984

PUB-NO: EP000107845A2

DOCUMENT-IDENTIFIER: EP 107845 A2

TITLE: Vaccine for immunizing cattle against infectious bovine keratoconjunctivitis by Moraxella Bovis.

PUBN-DATE: May 9, 1984

INVENTOR-INFORMATION:

NAME

COUNTRY

BRINTON, CHARLES C

GOODNOW, ROBERT A

ASSIGNEE-INFORMATION:

NAME

COUNTRY

BACTEX INC

US

APPL-NO: EP83110511

APPL-DATE: October 21, 1983

PRIORITY-DATA: US43784382A (October 29, 1982)

US-CL-CURRENT: 424/242.1; 424/251.1

INT-CL (IPC): A61K 39/02

EUR-CL (EPC): A61K039/02

ABSTRACT:

CHG DATE=19990617 STATUS=O> A vaccine for protecting cattle against Infectious Bovine Keratoconjunctivitis infection by a first group of strains of Moraxella bovis (M. bovis) contains pili of one or more members of a second group of strains of M. bovis which can induce antibodies to crossreact substantially completely with pili from the first group of strains.

WEST

Generate Collection

Print

L2: Entry 3 of 11

File: DWPI

Jun 11, 2002

DERWENT-ACC-NO: 2001-235092

DERWENT-WEEK: 200248

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Novel Moraxella bovis antigen useful in compositions for raising immune response in an animal, has protease, lipase or hemolysin activity

INVENTOR: FAM, J; STRUGNELL, R ; TENNENT, J ; FARN, J

PATENT-ASSIGNEE: COMMONWEALTH SCI & IND RES ORG (CSIR), UNIV MELBOURNE (UYME)

PRIORITY-DATA: 1999AU-0002571 (August 31, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
BR 200013574 A	June 11, 2002		000	C07K014/22
WO 200116172 A1	March 8, 2001	E	060	C07K014/22
AU 200068116 A	March 26, 2001		000	C07K014/22
EP 1210364 A1	June 5, 2002	E	000	C07K014/22

DESIGNATED-STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW AT BE CH CY DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
BR 200013574A	August 31, 2000	2000BR-0013574	
BR 200013574A	August 31, 2000	2000WO-AU01048	
BR 200013574A		WO 200116172	Based on
WO 200116172A1	August 31, 2000	2000WO-AU01048	
AU 200068116A	August 31, 2000	2000AU-0068116	
AU 200068116A		WO 200116172	Based on
EP 1210364A1	August 31, 2000	2000EP-0955974	
EP 1210364A1	August 31, 2000	2000WO-AU01048	
EP 1210364A1		WO 200116172	Based on

INT-CL (IPC): A61 K 38/48; A61 K 39/095; C07 K 14/22; C07 K 16/12; C12 N 15/31

ABSTRACTED-PUB-NO: WO 200116172A

BASIC-ABSTRACT:

NOVELTY - New *Moraxella bovis* polypeptide (I) has amino acids (aa) 37-1114 of a sequence (S1) comprising 1114 aa.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a nucleic acid molecule (II) comprising a sequence encoding (I);
- (2) a nucleic acid molecule (IIa) comprising a sequence (S4) of 4384 nucleotides, a sequence with at least 60% identity to S4, or a sequence which hybridizes under stringent conditions to S4;
- (3) a *Moraxella bovis* polypeptide (III) which has aa 26-616 of a sequence (S2) comprising 616 aa;
- (4) a nucleic acid molecule (IV) comprising a sequence encoding (III);
- (5) a nucleic acid molecule (IVa) comprising a sequence (S5) of 2110 nucleotides, a sequence with at least 60% identity to S5, or a sequence which hybridizes under stringent conditions to S5;
- (6) a *Moraxella bovis* polypeptide (V) which has a sequence (S3) comprising 927 aa or a sequence with at least 60% identity to S3 or a functional fragment of S3;
- (7) a nucleic acid molecule (VI) comprising a sequence encoding (V);
- (8) a nucleic acid molecule (VIa) comprising a sequence (S6) of 3231 nucleotides, a sequence with at least 60% identity to S6, or a sequence which hybridizes under stringent conditions to S6; and
- (9) an antibody raised against (I), (III) or (V).

ACTIVITY - Antibacterial.

MECHANISM OF ACTION - Vaccine. No supporting data given.

USE - (I)-(VI) are useful for raising an immune response in an animal directed against Moraxella, preferably against *M. bovis* or *M. catarrhalis* (claimed), and for treating Moraxella infections.

ABSTRACTED-PUB-NO: WO 200116172A

EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/5

DERWENT-CLASS: B04 D16

CPI-CODES: B04-E03E; B04-G03; B04-L05A; B04-L05C; B14-A01A; B14-S11B; D05-H11; D05-H12A;

WEST

Generate Collection

Print

L2: Entry 4 of 11

File: DWPI

Feb 10, 2000

DERWENT-ACC-NO: 2000-570723

DERWENT-WEEK: 200053

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Strain of Moraxella bovis g97-vnivi used for preparing diagnostica and vaccines against infectious keratoconjunctivitis in cattle

INVENTOR: GAFFAROV KH, Z; KHABIBULLIN F SH, ; SPIRIDONOV, G N ; VALEBNAYA, L V

PATENT-ASSIGNEE: VETERINARY RES INST (VETER)

PRIORITY-DATA: 1998RU-0117150 (September 15, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
RU 2145353 C1	February 10, 2000		000	C12N001/20

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
RU 2145353C1	September 15, 1998	1998RU-0117150	

INT-CL (IPC): A61 K 39/095; C12 N 1/20; G01 N 33/569

ABSTRACTED-PUB-NO: RU 2145353C

BASIC-ABSTRACT:

NOVELTY - A preparation used for diagnosis and prophylaxis of infectious keratoconjunctivitis in cattle. New strain of *Moraxella bovis* G97-VNIVI is deposited in microorganism collection of VNIVI. Strain retains S-form stably, it does not dissociate in multiple resowings and has the complete set of antigens that are typical for *M. bovis*. Invention ensures to prevent the propagation of infectious keratoconjunctivitis in cattle.

USE - Veterinary science, agriculture, microbiology.

ADVANTAGE - Enhanced effectiveness of preparations, decreased economical loss.

ABSTRACTED-PUB-NO: RU 2145353C

EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/0

DERWENT-CLASS: B04 C06 D16 S03 S05

CPI-CODES: B04-F10A; B12-K04A; B14-N03; C04-F10A; C12-K04A; C14-N03; D05-H07;

EPI-CODES: S03-E14H4; S05-C09;

WEST

Generate Collection

Print

L2: Entry 5 of 11

File: DWPI

Mar 28, 2000

DERWENT-ACC-NO: 1998-230316

DERWENT-WEEK: 200023

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Therapeutic proteinaceous substances from *Staphylococcus aureus* - useful to inhibit growth of wide range of prokaryotic or eukaryotic cells, e.g. Moraxella bovis causing infectious bovine keratoconjunctivitis

INVENTOR: CRUPPER, S; IANDOLO, J J ; CRUPPER, S S

PATENT-ASSIGNEE: UNIV KANSAS STATE RES FOUND (UNIV)

PRIORITY-DATA: 1997US-0931999 (September 17, 1997), 1996US-0710561 (September 19, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6043219 A	March 28, 2000		000	A61K038/02
WO 9812319 A1	March 26, 1998	E	038	C12N015/11

DESIGNATED-STATES: CA JP MX AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
US 6043219A	September 19, 1996	1996US-0710561	CIP of
US 6043219A	September 17, 1997	1997US-0931999	
WO 9812319A1	September 18, 1997	1997WO-US16758	

INT-CL (IPC): A61 K 38/02; A61 K 38/16; A61 K 39/085; C07 K 2/00; C07 K 14/00; C07 K 14/31; C12 N 15/11; G01 N 33/569

ABSTRACTED-PUB-NO: US 6043219A

BASIC-ABSTRACT:

Recombinant therapeutic proteinaceous substance with molecular weight < 4 kDa and having at least 80 % identity to sequence (I) produced by *Staphylococcus aureus* UT0007 (ATCC 55800) is new.

Also claimed are:

(1) a 3.4 kDa peptide with sequence (I) for BacR1, optionally recombinantly derived, and

(2) an oligonucleotide encoding the sequence for BacR1 with 81 bp sequence (II), or oligonucleotide with 204 or 6755 bp sequences (III)-(IV) respectively given in the specification.

Leu Gly Gly Ala Ala Thr Gly Val Ile Gly Tyr Ile Ser Asn Gln Thr Cys Pro Thr Thr Ala Cys Thr Arg Ala Cys (I)

USE - The substances can be administered to inhibit the growth of prokaryotic or eukaryotic cells in an environment capable of sustaining such growth (claimed).

For example, one or more could be applied topically on skin to control bacterial growth, used as antibiotic(s) to prevent/eradicate bacterial infection in an animal or used, either chemically modified or unmodified, as anti-cancer agent(s). The substances have antimicrobial activity against many gram-positive and gram-negative organisms e.g. BacR1(1280 antimicrobial units (AU)/ml) killed important pathogens *Bordetella brochoseptica*, *Pasteurella multocida* or *Staphylococcus aureus*; *Moraxella bovis*, causing infectious bovine keratoconjunctivitis (an eye disease in cattle which causes severe pain and blindness, reducing grazing ability) was especially sensitive.

ABSTRACTED-PUB-NO: WO 9812319A

EQUIVALENT-ABSTRACTS:

Recombinant therapeutic proteinaceous substance with molecular weight < 4 kDa and having at least 80 % identity to sequence (I) produced by *Staphylococcus aureus* UT0007 (ATCC 55800) is new.

Also claimed are:

(1) a 3.4 kDa peptide with sequence (I) for BacR1, optionally recombinantly derived, and

(2) an oligonucleotide encoding the sequence for BacR1 with 81 bp sequence (II), or oligonucleotide with 204 or 6755 bp sequences (III)-(IV) respectively given in the specification.

Leu Gly Gly Ala Ala Thr Gly Val Ile Gly Tyr Ile Ser Asn Gln Thr Cys Pro Thr Thr Ala Cys Thr Arg Ala Cys (I)

USE - The substances can be administered to inhibit the growth of prokaryotic or eukaryotic cells in an environment capable of sustaining such growth (claimed).

For example, one or more could be applied topically on skin to control bacterial growth, used as antibiotic(s) to prevent/eradicate bacterial infection in an animal or used, either chemically modified or unmodified, as anti-cancer agent(s). The substances have antimicrobial activity against many gram-positive and gram-negative organisms e.g. BacR1(1280 antimicrobial units (AU)/ml) killed important pathogens *Bordetella brochoseptica*, *Pasteurella multocida* or *Staphylococcus aureus*; *Moraxella bovis*, causing infectious bovine keratoconjunctivitis (an eye disease in cattle which causes severe pain and blindness, reducing grazing ability) was especially sensitive.

CHOSEN-DRAWING: Dwg.0/10

DERWENT-CLASS: B04 D16 S03

CPI-CODES: B02-Z; B04-B03C; B04-N03; B14-A01; B14-H01; D05-H12A; D05-H17A;

EPI-CODES: S03-E14H4;